Cellectis up on encouraging UCART22 data in leukemia

• Thinly traded small cap Cellectis S.A. (CLLS +4.2%) perks up on modest volume in reaction to preliminary data from a dose-escalation Phase 1 clinical trial, BALLI-01, evaluating cell therapy UCART22 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). The results will be presented at ASH in early December.
• The abstract includes interim data on the first five patients who received escalating doses of UCART22 cells after fludarabine/cyclophosphamide (FC) lymphodepletion.
• Two of the three receiving the first dose level responded, one complete responder and one complete responder with incomplete hematologic recovery.
• One patient receiving the second dose level achieved a "noteworthy" reduction in bone marrow blasts.
• On the safety front, four participants experienced treatment-related adverse events, mainly mild or moderate, consisting primarily of abnormalities in liver function biomarkers. Three experienced mild/moderate cytokine release syndrome. Two experienced serious treatment-emergent adverse events, one with Grade 3 febrile neutropenia and Grade 3 hepatic hematoma and one with life-threatening bleeding who died due to sepsis in the context of progressive disease.
• https://seekingalpha.com/news/3631128-cellectis-up-4-on-encouraging-ucart22-data-in-certain-leukemia-patients